Study guide
5.1 Pain and Analgesia in the ICU
Board Certified Critical Care Pharmacist Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pathophysiology and Recognition of Critical Illness
1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness
2 Chapter 2: Medical Devices and Circulatory Support
2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care
3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management
3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation
4 Chapter 4: Vasoactive and Inotropic Therapy in Shock
4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock
5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)
5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness
6 Chapter 6: Cardiovascular Emergencies
6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias
7 Chapter 7: Pulmonary and Infectious Diseases in the ICU
7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU
8 Chapter 8: Neurocritical Care
8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury
9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies
9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy
10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition
10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral
11 Chapter 11: Quality, Safety, and Clinical Guidelines
11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions
12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine
12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management
13 Chapter 13: Treatment Planning and Care Coordination
13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education
5.1 Pain and Analgesia in the ICU
Key Takeaways Explain This Topic AI
Pain is subjective and should be routinely assessed using validated scales like CPOT or BPS in critically ill patients who cannot self-report.
An 'analgesia-first' (analgosedation) approach is recommended, meaning pain should be treated before administering sedatives.
Opioids remain the mainstay for non-neuropathic pain, but multi-modal analgesia (acetaminophen, ketamine, gabapentinoids) helps reduce opioid requirements.
Fentanyl, hydromorphone, and morphine have distinct pharmacokinetic profiles that dictate their use in renal or hepatic impairment.
Last updated: July 2026
Pain and Analgesia in the ICU
Pain is a universal experience for critically ill patients, originating from underlying illnesses, trauma, surgical incisions, and routine ICU procedures (e.g., endotracheal suctioning, turning, catheter insertion). The Society of Critical Care Medicine (SCCM) Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption (PADIS) guidelines strongly emphasize the importance of routine pain assessment and management as the foundational step in ICU care.
Assessment of Pain
Accurate pain assessment is crucial because untreated pain can lead to agitation, increased myocardial oxygen consumption, immune suppression, and psychological trauma (e.g., PTSD). Conversely, over-treatment can result in respiratory depression, hypotension, and delayed extubation.
Self-Reporting
Whenever possible, the patient's self-report is the gold standard for pain assessment. The Numeric Rating Scale (NRS) (0-10) is most commonly used. However, many ICU patients are intubated, sedated, or delirious, rendering them unable to communicate reliably.
Validated Behavioral Scales
For adult ICU patients who cannot self-report, the PADIS guidelines recommend using validated behavioral pain scales. The two most prominent are:
Critical-Care Pain Observation Tool (CPOT): Assesses four domains: facial expression, body movements, muscle tension, and compliance with the ventilator (or vocalization for extubated patients). Each domain is scored 0-2 (total score 0-8). A score > 2 typically indicates significant pain.
Behavioral Pain Scale (BPS): Evaluates three domains: facial expression, upper limb movements, and compliance with mechanical ventilation. Each is scored 1-4 (total score 3-12). A score > 5 generally warrants intervention.
It is important to note that vital signs (heart rate, blood pressure) are not valid indicators for pain assessment in the ICU, as they can be influenced by numerous other factors (e.g., hypovolemia, inotropes, fever).
Analgesia-First (Analgosedation) Approach
The "analgesia-first" or analgosedation strategy prioritizes the treatment of pain before administering sedative medications. Often, treating pain adequately eliminates the need for continuous sedation. If sedation is still required after pain is controlled, it should be titrated to the lightest effective level.
- Benefits of Analgosedation
- Decreased duration of mechanical ventilation
- Reduced ICU length of stay
- Lower incidence of delirium
- Pharmacologic Management
- Opioids
Intravenous opioids are the primary agents for managing non-neuropathic pain in critically ill patients. They provide potent analgesia but carry risks such as respiratory depression, hypotension, and gastrointestinal dysmotility (ileus).
Opioid Onset Duration Active Metabolites Considerations
Fentanyl Rapid (1-2 min) Short (30-60 min) None Highly lipophilic. Can accumulate with prolonged infusions, leading to delayed awakening. Preferred in hemodynamic instability or renal failure.
Hydromorphone Intermediate (5-15 min) 2-4 hours None Lacks active metabolites, making it a safe option in renal impairment. Less histamine release than morphine.
Morphine Slower (10-20 min) 2-4 hours Yes (M3G, M6G) Causes histamine release (hypotension). Active metabolites accumulate in renal failure, leading to prolonged sedation and neurotoxicity.
Multimodal Analgesia
To minimize opioid consumption and mitigate opioid-related adverse effects, the PADIS guidelines strongly advocate for multimodal analgesia. This involves using medications with different mechanisms of action synergistically.
Acetaminophen (Paracetamol): Can be used as an adjunct to decrease opioid requirements. The IV formulation is effective but costly; enteral administration is preferred when feasible. Caution is required in severe hepatic impairment.
Ketamine: An NMDA receptor antagonist that provides potent analgesia at sub-anesthetic doses (e.g., 0.1-0.3 mg/kg/hr) without causing respiratory depression. It can reduce opioid consumption but may cause psychotomimetic effects (hallucinations), though these are rare at low doses.
NSAIDs/Ketorolac: Effective for bone or inflammatory pain, but their use in the ICU is limited due to the risks of acute kidney injury (AKI), gastrointestinal bleeding, and platelet inhibition.
Gabapentinoids (Gabapentin, Pregabalin): Recommended specifically for neuropathic pain. They are typically administered enterally and require dose adjustment in renal impairment.
Lidocaine: IV lidocaine infusions may be considered for postoperative pain in abdominal surgery patients, though strict monitoring for local anesthetic systemic toxicity (LAST) is required.
Clinical Scenario
A 68-year-old male with a history of heart failure (LVEF 30%) and chronic kidney disease (baseline creatinine 2.5 mg/dL) is admitted to the ICU following an emergency laparotomy for a perforated bowel. He is mechanically ventilated. He is grimacing, thrashing in bed, and fighting the ventilator. His CPOT score is 6.
Discussion: The patient is clearly experiencing pain (CPOT 6) and requires immediate analgesia. Given his renal dysfunction, morphine should be avoided due to the accumulation of active metabolites. Fentanyl or hydromorphone would be preferred. Fentanyl's rapid onset and minimal hemodynamic effects make it an excellent choice for this acute scenario. Multimodal adjuncts like IV acetaminophen could be added, but NSAIDs are contraindicated given his CKD.